Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 4/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20670745 | 0.78 | GRN (0.33) | — | |
| SCHEMBL20670622 | 0.75 | GGPS1 (0.31) | — | |
| SCHEMBL20670747 | 0.75 | HSP90AB1 (0.40) | P2RX7HSP90AB1 | |
| SCHEMBL20650984 | 0.70 | LOXL2 (0.34) | NPC1HSP90AB1 | |
| SCHEMBL16851358 | 0.69 | P2RX7 (0.39) | NPC1P2RX7CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18623684 | 0.67 | NOTUM (0.43) | NPC1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL15257082 | 0.66 | APP (0.39) | HSP90AB1 | |
| SCHEMBL25511940 | 0.66 | NPC1 (0.33) | NPC1P2RX7CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25751753 | 0.66 | RXRA (0.35) | NPC1P2RX7CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24894321 | 0.66 | NOTUM (0.39) | NPC1CYP1A2CYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190023732-A1 | OLIGONUCLEOTIDES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023732-A1 | OLIGONUCLEOTIDES | NSUN3, DCLRE1B, TRDMT1 | NPC1 1595/4885P2RX7 784/4885CYP1A2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.